Anders Grøn joins Clinical Microbiomics as new CEO

Clinical Microbiomics prepares for its next growth phase with a new CEO, Anders Grøn, who took the lead on October 1st, 2021. Anders replaces Martin Santini, who has successfully led Clinical Microbiomics since 2016, and who has now chosen to look for new challenges.

Anders Grøn comes from a position as Group Vice President of IFF (prev. Dupont), and global leader for IFF Health, including the activities within probiotics, Human Milk Oligosaccharides and other microbiome focused solutions. Before that Anders held leading positions at Coloplast and Chr. Hansen.

On the choice of Anders Grøn, Chairman of Clinical Microbiomics, Morten Sommer, says: “Anders Grøn has worked internationally to develop commercial organizations and has achieved impressive results in industries within the field where Clinical Microbiomics and its customers operate. The Board of Directors and owners are convinced that Anders has the profile to fulfill the potential of Clinical Microbiomics in this next phase of its development, which is about offering, developing, and bringing to market advanced microbiome analyses for customers within pharma, consumer health, biotech, and academia”.

Anders Grøn will be leading the continued development of Clinical Microbiomics, focusing on global expansion and scientific leadership within the microbiome field. Anders sees significant potential in Clinical Microbiomics: ”We have only scratched the surface of how the microbiome may impact our health and well-being. The number of clinical studies is growing at a fast pace, and we have seen several successful phase 3 studies over the last years. We see a corresponding development in the bioinformatical toolset. I have a great deal of respect for the technology and expertise that management and employees of Clinical Microbiomics have created so far. The company is a technology leader in its field and could be become a crucial partner for the healthcare sector globally. I am looking forward to realizing the significant potential in cooperation with employees, customers, and other key partners.”

The executive management of Clinical Microbiomics will be Anders Grøn (CEO), Henrik Bjørn Nielsen (CSO), and Henrik Knudsen (CFO/COO).

Briefly about Anders Grøn:

  • MSc from Copenhagen Business School and management certificates from Yale and IMD
  • 2005-2011: employed at DuPont (Danisco) in various regional and global positions in the commercial organization.
  • 2011-2013: employed at Chr. Hansen with responsibility for the commercial development of a business area within the Cultures & Enzymes division.
  • 2013-2015: Director at Coloplast with responsibility for the global Ostomy Care Business unit.
  • 2015-2021: VP at IFF (DuPont) with global responsibility for IFF Health, including probiotics, HMO, and other microbiome-based solutions.

Clinical Microbiomics in short:

Clinical Microbiomics was founded in 2015 by Professor Morten Sommer and serial entrepreneur Rasmus Toft-Kehler. The company is a market leader in microbiome research, bioinformatics, and machine learning. Led by Chief Science Officer Henrik Bjørn Nielsen, Clinical Microbiomics has developed a number of innovative computational methods for microbiome analysis. The company offers its services within the full range of the value chain, from data generation to customized statistical analysis and interpretation of findings. The primary focus is on advanced bioinformatical tools developed in-house, making Clinical Microbiomics a market leader when it comes to extracting insight from microbiome and clinical data. The company has built up a strong portfolio of customers in probiotics and the Human Milk Oligosaccharides segment and is working with several biotech companies on phase 3 clinical trials. The business model covers contract research and discovery partnerships with an emphasis on “next generation” probiotics and the identification of non-invasive microbiome biomarkers, covering a variety of diseases, including IBD and metabolic disorders.

Clinical Microbiomics is one of several successful biotech and life science companies founded by serial entrepreneurs Morten Sommer and Rasmus Toft-Kehler.

Get in touch

Tell us about your study.

Please enable JavaScript in your browser to complete this form.